SUPPLEMENTAL DIGITAL CONTENT 1

SUPPLEMENTAL TABLE 1. Patient Demographics and Baseline Disease Characteristics

Parameter	RPV 25 mg QD N = 686	EFV 600 mg QD N = 682
Female, n (%)	168 (24)	163 (24)
Region, n (%)		
USA, Canada, Europe, Australia	379 (55)	347 (51)
Africa	51 (7)	69 (10)
Asia	106 (15)	112 (16)
Latin America	150 (22)	154 (23)
Median age (range), years	36 (18–78)	36 (19–69)
Race, n (%)		
Caucasian/White	420 (61)	410 (60)
Black/African American	165 (24)	156 (23)
Asian	78 (11)	97 (14)
Other*	21 (3)	19 (3)
Median viral load (range), $\log_{10}$ copies per milliliter	5 (2–7)	5 (3–7)
Median $CD4^+$ cell count (range), cells/mm^3	249 (1–888)	260 (1–1137)
Median duration of known HIV infection (range), years	1.4 (0–24)	1.3 (0–28)
Baseline viral load ≤100,000 copies per milliliter, n (%)	368 (54)	330 (48)
Baseline viral load >100,000–≤500,000 copies per milliliter, n (%)	249 (36)	270 (40)
Baseline viral load >500,000 copies per milliliter, n (%)	69 (10)	82 (12)
Hepatitis B or C coinfection, n (%)	49 (7)	63 (9)
Initial background regimen, n (%)		
TDF/FTC	550 (80)	546 (80)
AZT/3TC	101 (15)	103 (15)
ABC/3TC	35 (5)	33 (5)

*Includes patients whose race was other than those presented and for whom information on race was missing.

RPV, rilpivirine; EFV, efavirenz; QD, once daily; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; AZT, zidovudine; 3TC, lamivudine; ABC, abacavir; N, number of patients in each treatment group; n = number of observations.